AB0075 EFFECT OF SIDAGURI EXTRACT (SIDA RHOMBIFOLIA L) ON URINARY CARBOXY-TERMINAL TELEPEPTIDES OF TYPE II COLLAGEN IN OSTEOARTHRITIC PATIENTS
Authors: Blondina Marpaung, Sheena Dalimunthe, Joshua Patrick, William Simanjuntak
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Osteoarthritis is one of the most common joint diseases in Indonesia and elsewhere. Assessment of the effectiveness of osteoarthritis therapy with biomarkers should be developed. One of the biomarker that can be used to assess the activity of osteoarthritis is <i>Urinary Carboxy-Terminal Telepeptides of Type II Collagen</i>. Indonesia is the center of world biodiversity, and Sidaguri is one of the traditional plants that is believed to have many benefits including its anti-inflammatory effect and the ability to decrease level of uric acid. The β-sitosterol is an active component in Sidaguri that has anti-inflammatory activity in osteoarthritis. <h3>Objectives:</h3> To compare the effect of sidaguri and meloxicam therapy with meloxicam alone in decreasing the levels of urinary Carboxy-Terminal Telepeptides Of Type II Collagen in osteoarthritis patients. <h3>Methods:</h3> This study was conducted on 24 patients with osteoarthritis at H. Adam Malik General Hospital Medan from April to June 2018. Subjects were divided into 2 groups, namely placebo and Sidaguri group. Levels of uCTX II were assessed before and after intervention. T- test was used to analyze the data using SPSS version 22. <h3>Results:</h3> 83.3% of osteoarthritis patients in H. Adam Malik hospital who participated in this study were women with mean age 60.58 ± 9.74 years in the placebo group and 63.08 ± 6.14 years in the sidaguri group. The results showed that subjects receiving Sidaguri showed significant decrease in uCTX II before and after intervention (521.42 ± 369.99 vs 330.75 ± 163.49 ng/mmol, p = 0.033). Meanwhile, in the placebo group also found decreased levels of uCTX II but it was not statistically significant (286.17 ± 163.82 vs. 218.25 ± 75.05 ng/mmol, p = 0.238). In addition, there was a significant difference between the mean of the two groups after the intervention (p = 0.046). <h3>Conclusion:</h3> There was a significant decrease in uCTX II levels in osteoarthritis patients who received Sidaguri extract for 30 days compared to the placebo group. <h3>References</h3> [1] Aigner, T, et al. 2015. Pathogenesis and Pathology of Osteoarthritis. In : Hochberg. M, Silman. A, Smolen. J, Weinblat. M, Weisman. M, editors. Rheumatology. 6th ed.Philadelphia : Elsevier; p.1462-1476. [2] Alpiansyah, A. 2015. Antihyperuricemia Potential of Sida rhombifolia L. as a Treatment for Gout. Journal Majority. Vol. 4 (3):9-13. [3] Davies NM., Skjodt NM,. 1999. Clinical Pharmakinetics of Meloxicam. Clin Pharmacokinet Feb;36(2):115-126. [4] Gupta MB, et al. 1980. Anti-inflammatory and antipyretic activities of beta-sitosterol. Planta Med. 1980 Jun;39(2):157-63 [5] Marpaung, B. 2010. Penggunaan Petanda Biokimia Asam Hialuronat Serum Dan CTX-II Urin Terhadap Penilaian Hasil Pengobatan Osteoartritis Lutut. Medan : University of Sumatera Utara Institutional Repository <h3>Disclosure of Interests:</h3> None declared